Agomelatine Augmentation Added to SSRIs or SNRIs for Depression
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy and safety of agomelatine augmentation
antidepressant therapy in patients with major depressive disorder with inadequate response
during early stage of treatment.